Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study

Trial Profile

Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Takayasu syndrome
  • Focus Therapeutic Use
  • Acronyms TOCITAKA
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Apr 2016 to 10 Dec 2019.
    • 28 Aug 2017 Planned primary completion date changed from 1 Apr 2015 to 10 Dec 2018.
    • 15 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top